{"id":2269,"date":"2010-12-01T13:37:10","date_gmt":"2010-12-01T18:37:10","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=2269"},"modified":"2010-12-01T13:37:10","modified_gmt":"2010-12-01T18:37:10","slug":"rd-collaboration-to-discover-drugs-for-river-blindness","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=2269","title":{"rendered":"R&#038;D Collaboration to Discover Drugs for River Blindness"},"content":{"rendered":"<figure id=\"attachment_2271\" aria-describedby=\"caption-attachment-2271\" style=\"width: 265px\" class=\"wp-caption alignleft\"><a href=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/12\/riverblindness-200_AmericaGov.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-2271\" title=\"riverblindness-200_AmericaGov\" src=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/12\/riverblindness-200_AmericaGov.jpg\" alt=\"River blindness (America.gov)\" width=\"265\" height=\"200\" srcset=\"https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/12\/riverblindness-200_AmericaGov.jpg 265w, https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/12\/riverblindness-200_AmericaGov-150x113.jpg 150w\" sizes=\"auto, (max-width: 265px) 100vw, 265px\" \/><\/a><figcaption id=\"caption-attachment-2271\" class=\"wp-caption-text\">(America.gov)<\/figcaption><\/figure>\n<p>Anacor Pharmaceuticals in Palo Alto California, the University of California San Francisco&#8217;s Sandler Center and the Lindsley F. Kimball Research Institute (LFKRI) of the New York Blood Center established a <a href=\"http:\/\/investor.anacor.com\/releasedetail.cfm?ReleaseID=533909\">research and development collaboration<\/a> to discover new therapies to treat river blindness (onchocerciasis). <a href=\"http:\/\/emedicine.medscape.com\/article\/1109409-overview\">River blindness<\/a> is a parasitic disease and the second leading cause of infectious blindness worldwide, affecting 37 million people, particularly in Africa.<\/p>\n<p>The collaboration will combine Anacor&#8217;s chemistry platform, and drug discovery and development capabilities, with the Sandler Center&#8217;s expertise in neglected disease biology and drug discovery and the LFKRI&#8217;s expertise in onchocerciasis. Their goal is to identify a potent drug candidate capable of killing adult worms. Current medications kill only microfilaria &#8212; the pre-larval stage of the worm &#8212; which means treating the same infected individual repeatedly over several years to outlast the lifetime of the adult worms and to stop transmission of the disease. A drug that kills adult worms would simplify ongoing elimination programs for river blindness and improve outcomes for patients and communities affected by the disease.<\/p>\n<p>The collaboration also includes the BioComputing and Media Research Group at San Francisco State University which will develop algorithms and software to automate the screening process for lead identification.<\/p>\n<p>Funding for the project is being provided by the Bill and Melinda Gates Foundation through a grant to UCSF over two years for a total of $3.61 million, of which Anacor will receive $2.24 million.<\/p>\n<p style=\"text-align: center;\">*\u00a0\u00a0\u00a0\u00a0 *\u00a0\u00a0\u00a0\u00a0 *<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Anacor Pharmaceuticals in Palo Alto California, the University of California San Francisco&#8217;s Sandler Center and the Lindsley F. Kimball Research Institute (LFKRI) of the New York Blood Center established a research and development collaboration to discover new therapies to treat river blindness (onchocerciasis). River blindness is a parasitic disease and the second leading cause of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3,16],"tags":[31,21,38,64,27,26],"class_list":["post-2269","post","type-post","status-publish","format-standard","hentry","category-finance","category-ventures","tag-biomedical","tag-biotech","tag-grant","tag-life-sciences","tag-pharmaceuticals","tag-university"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/2269","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2269"}],"version-history":[{"count":2,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/2269\/revisions"}],"predecessor-version":[{"id":2272,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/2269\/revisions\/2272"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2269"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2269"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2269"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}